Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AWZ1066S in Healthy Volunteers
NCT05084560Phase 1Terminated
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lymphatic filariasis (LF) and onchocerciasis comparing AWZ1066S with Placebo (2 arms). Primary endpoint: Adverse events. Started Dec 2021; status: terminated.
02
Drugs
awz1066s
03
Conditions
lymphatic filariasis (LF)onchocerciasis
Beyond the preview
Go deeper on NCT05084560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084560.